March 2026 brought meaningful advances in aesthetic medicine, from new FDA-approved options for managing GLP-1-related facial volume loss to strengthening clinical evidence for polynucleotide and exosome therapies. This roundup covers the developments most relevant to certified aesthetic providers, including new consensus guidance, shifting patient demographics, and an evolving regulatory landscape.
Two oral GLP-1 medications for obesity are now FDA-approved — Eli Lilly’s Foundayo (orforglipron) and Novo Nordisk’s Wegovy pill (semaglutide 25 mg) — and they are meaningfully different. This clinical comparison breaks down the trial data, dosing requirements, and pricing so providers can have informed conversations with patients.
Insurance-based practice has become one of the leading structural drivers of physician burnout — but the solution is not a wellness seminar. For a growing number of physicians, cash-based aesthetic medicine is the deliberate exit strategy that removes the administrative burden and puts them back in control of their time and income.
The retatrutide warning is one every GLP-1 provider needs to hear before a patient asks about it. This investigational drug is not FDA-approved, cannot legally be compounded, and sourcing it could leave your practice without malpractice coverage.
The FDA has approved Wegovy 7.2 mg, tripling the previous maximum dose of high-dose semaglutide and raising important new questions about patient selection, safety, and the role of lifestyle support. Here is what medical weight loss providers need to know before this higher-dose option reaches U.S. pharmacies in April 2026.
Temple hollowing has become a hallmark of “Ozempic face” in GLP‑1 patients, often making people look older even as their health improves. This article explains how Restylane Contour’s new FDA approval for temple hollowing fits into safe, staged treatment planning for this rapidly growing patient group.
February 2026 brought a wave of clinical evidence that moves the conversation in aesthetic medicine from trend awareness to data-informed decision-making. From a landmark head-to-head neurotoxin comparison to new quantifiable metrics on GLP-1-related facial volume loss, this month’s research gives physicians and nurse practitioners a stronger foundation for protocol development, patient counseling, and practice growth.
Every profitable aesthetic practice is built on three core services: injectables, lasers, and facial rejuvenation. Learn which service to start with, how much revenue each generates, and how to expand strategically as your practice grows.
A new 2026 study published in the Journal of Cosmetic Dermatology reveals how combining Microneedle Fractional Radiofrequency (MFR) with Platelet-Rich Plasma (PRP) offers targeted advantages for treating complex melasma. For providers entering aesthetic medicine, this research demonstrates why advanced combination therapies are essential for building a modern, profitable practice beyond basic injectables.
Letybo, South Korea’s #1 neurotoxin, has officially launched in the U.S., offering providers a faster-onset alternative to Botox with a competitive price point. This comprehensive guide breaks down how Letybo compares to Botox and Daxxify, who makes an ideal candidate, and whether this new product deserves a place in your practice.